<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02882295</url>
  </required_header>
  <id_info>
    <org_study_id>SSA_2016_10</org_study_id>
    <nct_id>NCT02882295</nct_id>
  </id_info>
  <brief_title>Validation of the Zigzag Tracking Task Test for the Evaluation of Handwriting Difficulties in Writer's Cramp</brief_title>
  <acronym>LabyDys</acronym>
  <sponsors>
    <lead_sponsor>
      <agency>Fondation Ophtalmologique Adolphe de Rothschild</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fondation Ophtalmologique Adolphe de Rothschild</source>
  <brief_summary>
    <textblock>
      Writer's cramp (WC) is a task specific dystonia that occurs from the moment patient starts&#xD;
      writing. It leads to partial or complete inability to use the hand only during the&#xD;
      handwriting gesture. It is characterized by the appearance of cramps or spasms of certain&#xD;
      muscles of the hand and/or forearm.&#xD;
&#xD;
      Clinical scales currently use for the assessment of WC fail to accurately reflect changes in&#xD;
      the characteristics of handwriting in response to treatments (Botulinum Neurotoxin injections&#xD;
      and / or retraining therapy).&#xD;
&#xD;
      The Zigzag Tracking Task (ZZTT), easy to use in current practice provides useful information&#xD;
      in terms of speed and precision of handwriting gesture. This timed handwriting test is to&#xD;
      follow with a pen a zigzag path beset with obstacles to avoid. It permits to evaluate the&#xD;
      time in seconds required to carry out the zigzag path and count the number of errors (output&#xD;
      path and contacts with obstacles). The investigators propose to validate the ZZTT for the&#xD;
      assessment of the handwriting gesture of WC.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 2016</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>hand-writing speed</measure>
    <time_frame>immediate</time_frame>
    <description>speed and accuracy of handwriting</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Dystonic Disorder</condition>
  <arm_group>
    <arm_group_label>writer's cramp</arm_group_label>
    <description>patients assessed without, then with Botulinum Neurotoxin injections</description>
  </arm_group>
  <arm_group>
    <arm_group_label>control</arm_group_label>
    <description>age and gender matched</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Validation of a handwriting scale</intervention_name>
    <arm_group_label>control</arm_group_label>
    <arm_group_label>writer's cramp</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        patients suffering from writer's cramp and healthy subjects, age and gender matched&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  scholarship in French language, at least until 16 years old&#xD;
&#xD;
          -  writer's cramp (diagnostic confirmed by a neurologist specialized in movement&#xD;
             disorders)&#xD;
&#xD;
          -  prescription of botulinum neurotoxin injection&#xD;
&#xD;
          -  prescription de novo or absence of injection in the last 3 months&#xD;
&#xD;
          -  informed consent&#xD;
&#xD;
          -  medical insurance coverage&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  writing tremor&#xD;
&#xD;
          -  -other neurological disease with effect on handwriting&#xD;
&#xD;
          -  pain or traumatism of the upper limb, with effect on handwriting&#xD;
&#xD;
          -  non-corrected visual disturbances&#xD;
&#xD;
          -  patient living outside the region where the study will be held (Ile-de-France)&#xD;
&#xD;
          -  participation in another research with a potential impact on evaluation criteria&#xD;
&#xD;
          -  pregnant or breast feeding patient&#xD;
&#xD;
          -  patient under judiciary protection&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jean-Pierre BLETON, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Fondation OPH A de Rothschild</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Sophie SANGLA, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fondation OPH A de Rothschild</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Laurence SALOMON, MD, PhD</last_name>
    <phone>0033148036431</phone>
    <email>lsalomon@for.paris</email>
  </overall_contact>
  <location>
    <facility>
      <name>Fondation Ophtalmique Adolphe de Rothschild</name>
      <address>
        <city>Paris</city>
        <zip>75019</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sophie Sangla, MD</last_name>
      <email>ssangla@fo-rothschild.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>August 24, 2016</study_first_submitted>
  <study_first_submitted_qc>August 26, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 29, 2016</study_first_posted>
  <last_update_submitted>July 16, 2021</last_update_submitted>
  <last_update_submitted_qc>July 16, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dystonic Disorders</mesh_term>
    <mesh_term>Dystonia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

